ReviewTranslational cancer research2026
Tumor cell plasticity in non-small cell lung cancer: the role of microRNA and implications for diagnosis, prognosis and treatment.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the leading causes of cancer morbidity and mortality worldwide. Majority of cases are diagnosed as late-stage disease. Non-small cell lung cancer (NSCLC) forms the major pathologic group of this disease. The highly malignant nature of NSCLC is mediated by tumor cell plasticity (TCP). Designated as a hallmark of cancer, it is the ability of cancer cells to reprogram its molecular cell state and behaviour in response to environmental stress. MicroRNAs (miRNA) play a major role in TCP of NSCLC from premalignant disease, tumor initiation, progression and invasion, immune evasion to metastasis. TCP mediated by miRNA include epithelial mesenchymal transition, cancer stem cell biology, and cross talk between cancer and its tumor microenvironment. An understanding of these mechanisms gives a more comprehensive and precise molecular profile of NSCLC behaviour and implications for diagnosis, prognosis, monitoring and treatment. Emerging technologies including liquid biopsy, tumor geospatial profiling and single cell RNA sequencing hold promise to transform the clinical management of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.